MCE 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务。
CAS No. : 1358099-18-9
MCE 国际站:C25-140
产品活性:C25-140 是一种首创的,具有口服活性和一定选择性的 TRAF6-Ubc13 相互作用的抑制剂,直接与 TRAF6 结合,阻断 TRAF6 和 Ubc13 的相互作用,从而降低 TRAF6 活性,降低 NF-κB 的活性,并对抗自身免疫。
研究领域:Apoptosis | Metabolic Enzyme/Protease
作用靶点:TNF Receptor | E1/E2/E3 Enzyme
In Vitro: C25-140 dose-dependently impedes TRAF6-Ubc13 interaction.
C25-140 (10-30 μM; 2 hours) effectively reduces TRAF6-mediated ubiquitin chain formation.
C25-140 affects TNFα-induced phosphorylation of IκBα as well as NF-κB-induced target gene expression.
C25-140 efficiently inhibits IL-1β- and TNFα-mediated receptor signaling in the context of cytokine activation.
In Vivo: C25-140 (~1.5 mg/kg; topically to the shaved back and the right ear; twice daily for 6 days) ameliorates symptoms of autoimmune psoriasis in R 837-induced psoriasis mouse model.
C25-140 (6-14 mg/kg; given i.p.; twice daily for 14 days) shows a dose-dependent improvement of RA disease outcome in Collagen-induced arthritis (CIA) model.
C25-140 (10 mg/kg; i.v.) treatment shows that the Cmax, AUC, t1/2 and Vd are 9.7 μg/mL, 274083 ng min/mL, 80.62 min, and 4.13 L/kg, respectively.
.C25-140 (10 mg/kg; p.o.) treatment shows that the Cmax, AUC, t1/2 and Vd are 3.4 μg/mL, 124034 ng min/mL, 127.33 min and 13.3 L/kg, respectively.
C25-140 (10 mg/kg; i.p.) treatment shows that the Cmax, AUC, t1/2 and Vd are 4.2μg/mL, 100000 ng min/mL, 184 min, 25.6 L/kg, respectively.
相关产品:Bioactive Compound Library Plus | Apoptosis Compound Library | Immunology/Inflammation Compound Library | Metabolism/Protease Compound Library | NF-κB Signaling Compound Library | Differentiation Inducing Compound Library | Oxygen Sensing Compound Library | Ubiquitination Compound Library | Pyroptosis Compound Library | Angiogenesis-Related Compound Library | Antidepressant Compound Library | Anti-Prostate Cancer Compound Library | Anti-Pulmonary Fibrosis Compound Library | Heterocyclic Compound Library | Mitochondrial Protection Compound Library | Membrane Protein-targeted Compound Library | Membrane Receptor-targeted Compound Library | Highly Selective Inhibitors Library | WSB1 Degrader 1 | Relfovetmab | Anti-Mouse TNF alpha Antibody | Apremilast | GS143 | QNZ | p53 and MDM2 proteins-interaction-inhibitor (racemic) | Navtemadlin | Broussonin E | Undecane | Utomilumab | 1,4-Dicaffeoylquinic acid | Asunercept | MX69 | Cetrelimab | RG7112 | Mulberroside A | Ginsenoside Rc | MD-224 | WS-383 free base | (Rac)-BIO8898 | Dordaviprone | Ubiquitination-IN-1 | UbcH5c-IN-1 | IW927 | p53-MDM2-IN-1 | Apratastat | Anti-inflammatory agent 16 | Sinulatumolin C | VGX-1027
热门产品线:重组蛋白 | 化合物库 | 天然产物 | 荧光染料 | PROTAC | 同位素标记物 | 寡核苷酸 | 抗体 | 点击化学
Trending products:Recombinant Proteins | Bioactive Screening Libraries | Natural Products | Fluorescent Dye | PROTAC | Isotope-Labeled Compounds | Oligonucleotides | Antibodies | Click Chemistry
货号: HY-120934
品牌介绍:
• MCE (MedChemExpress) 拥有200 多种全球独家化合物库,我们致力于为全球科研客户提供前沿最全的高品质小分子活性化合物;
• 50,000 多种高选择性抑制剂、激动剂涉及各热门信号通路及疾病领;
• 产品种类涵盖各种重组蛋白,多肽,常用试剂盒 ,更有 PROTAC、ADC 等特色产品,广泛应用于新药研发、生命科学等科研项目;
• 提供虚拟筛选,离子通道筛选,代谢组学分析检测分析,药物筛选等专业技术服务;
• 设有专业的实验中心和严格的质控、验证体系;
• 提供 LC/MS、NMR、HPLC、手性分析、元素分析等各项质检报告,确保产品的高纯度、高品质;
• 产品的生物活性多经各国客户实验验证;
• Nature, Cell, Science 等多种顶级期刊及制药专利收录了MCE客户的科研成果;
• 专业团队跟踪最新的制药及生命科学研究进展,为您提供全球最新的活性化合物;
• 与世界各大制药公司及知名科研机构建立了长期的合作。